Register as a Clinical site

Please indicate the radiopharmacy your center works with

Please, provide your Lu-177 radioisotope manufacturer information in the following fields.

Terms and conditions

Thank you for considering the use of the RLT-CONNECT Platform, which is operated by the Oncidium foundation.

 

This website is accessible only under registration. Your access to and use of this Website are subject to the terms of use set out below. These general terms of use contain legal information about your visit to and use of this Website, a declaration on intellectual property rights and a reference to the privacy legislation. Please read these terms of use carefully before visiting this Website or using it in any manner.

1. Agreement to Terms of Use

By using the RLT-CONNECT Platform, you agree to comply with and be bound by these Terms of Use. If you do not agree to these terms, you may not use the platform.

2. Operation

The RLT-CONNECT Platform is operated by the Oncidium foundation, a public-interest foundation based in Belgium. Registered under company number 0838.388.420 and having its headquarters at Avenue Herrmann-Debroux, 40, 1160 Brussels, Belgium.

3. Description

The purpose of the RLT-Connect Platform is to connect Health Care Practitioners (HCP) and Medical Radioisotope Companies (Suppliers) with the objective of making a treatment based on medical radioisotopes available, for patients who cannot afford such treatments

RLT-Connect Platform
The RLT-Connect Platform is a platform with restricted access, which can only be used for the purpose described above.

Free of charges
The access to and use of the RLT-Connect Platform is free of charges for the Supplier and the HCP.

Obligations of HCP
Any HCP who wishes to be provided with a RLT Product via the RLT-Connect Platform shall commit to comply with the Ethics Charter and to check that the patient is eligible to receiving the RLT Product concerned, i.e. such patient cannot afford the RLT Product and has the correct medical indication.

Non-exclusivity. The Supplier acknowledges and agrees that this Agreement is not exclusive and that Oncidium has therefore the right to call on the services of other Suppliers to participate in the RLT-Connect Platform and to supply RLT Products.

4. Disclaiming responsibilities

Role of the Oncidium foundation
The operations carried out through the RLT-Connect Platform are limited to:

  • (A) Facilitating the connections between the relevant stakeholders;
  • (B) Defining patient eligibility criteria and creating an Ethics Charter that shall be signed by the participating HCP;
  • (C) Evaluating HCP’s requests before they appear on the RLT-Connect Platform in light of eligibility criteria and Ethics Charter;
  • (D) Setting up and hosting the RLT-Connect Platform and thus enabling the sharing of information and contact between the HCP and the Suppliers;
  • (E) Managing the account of RLT-Connect Users and HCPs;
  • (F) The Oncidium foundation is not liable for actions, omissions and events for which it does not hold responsibility.

5. Limitation of Liability

The RLT-CONNECT Platform is provided on an "as-is" basis without any warranties of any kind. In no event shall the Oncidium foundation be liable for any damages arising from the use of the platform, including but not limited to direct, indirect, incidental, or consequential damages.

  • (A) The Oncidium foundation cannot guarantee that the form, dosage or amount of radioisotope dose required by the HCP will be made available through the Platform;
  • (B) The Suppliers are responsible for the information placed on the RLT-Connect Platform (including but not limited to the publication of available radioisotope doses). Each Supplier warrants and represents that such information is at all times accurate, updated, reflects the reality and is compliant with applicable laws, regulations and industry codes of practice. The Oncidium foundation bears no responsibility for the information placed on the RLT-Connect Platform by the Supplier;
  • (C) Transactions are subject to the conclusion of a separate negotiation between the HCP and the supplier concerned to establish delivery schedule and other necessary activities necessary for the conclusion of the Transaction. The Oncidium foundation will not be a part of such negotiations. Under no circumstances will the Oncidium foundation bear any responsibility for the Transaction(s);
  • (D) The Oncidium foundation does not take any responsibility for the compliance of the Transaction with countries’ applicable laws, regulations and industry codes of practice;
  • (E) The Oncidium foundation does not bear any responsibility for the transportation, importation, exportation, customs clearance and release of the radioisotopes to the HCP. Notwithstanding the generality of the foregoing, the Oncidium foundation does not bear responsibility for the completeness, conformity, quality or fitness-for-purpose of the radioisotope supplied by the Supplier to the HCP, including but not limited to the successful reconstitution/production of a radiopharmaceutical product based on an radioisotope received from a Supplier.;
  • (F) The Suppliers and HCP shall not provide any personal data of patients to the Oncidium foundation and they shall be responsible for the processing of personal data when they act as a data controller in the meaning of the GDPR.

6. Intellectual Property Rights

All content on the RLT-CONNECT Platform, including but not limited to software, images, graphics, texts, and logos, is the property of the Oncidium foundation or its licensors and is protected by Belgian and international copyright laws. You may not reproduce, modify, distribute, or otherwise use any content without the prior written consent of the Oncidium foundation.

7. Protection of personal data

We take the utmost care to protect the personal data you share with us. For further details, please refer to our privacy policy which has been published on this Website.

8. Legality of the terms of use

The provisions of these terms of use are without prejudice to the statutory, regulatory or mandatory provisions and to the public policy provisions applicable under Belgian or European law. As regards the applicability of these terms of use and their relationship with other legal texts produced by Oncidium foundation. The legality of the Transaction is responsibility of the HCP and Supplier concerned. Therefore, both parties should perform a legality check before entering into any Transaction according to the local and international laws regarding radioisotope transport and manipulation.

9. Belgian Governing Law

These Terms of Use shall be governed by and construed in accordance with the laws of Belgium, without giving effect to any principles of conflicts of law.

 

Thank you for your cooperation and support of Oncidium Foundation's mission to facilitate the donation of radiopharmaceuticals.